{"filing":{"accession_number":"0001171843-26-005223","cik":"0000882796","ticker":"BCRX","company_name":"BIOCRYST PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"f8k_080526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/f8k_080526.htm"},"events":[{"id":24429,"run_id":22135,"accession_number":"0001171843-26-005223","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BioCryst Pharmaceuticals issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including total net revenue of $218.3 million, operating profit of $98.5 million, and updated full-year 2026 guidance.","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24974,"accession_number":"0001171843-26-005223","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioCryst issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including total net revenue of $218.3 million, operating profit of $98.5 million, and updated full-year 2026 guidance. The filing includes consolidated financial statements and detailed discussion of quarterly performance, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:53.412022+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24975,"accession_number":"0001171843-26-005223","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing BioCryst's second quarter 2026 financial results, including total net revenue of $218.3 million, operating profit of $98.5 million, and updated full-year 2026 guidance. The filing explicitly states \"BioCryst Reports Second Quarter 2026 Financial Results\" and provides detailed financial statements and business updates, which is the hallmark of an earnings release disclosure under Item 2.02 (though filed under Item 7.01 as Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:53.412022+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24974,"accession_number":"0001171843-26-005223","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioCryst issued a press release on August 5, 2026 announcing its financial results for the second quarter ended June 30, 2026, including total net revenue of $218.3 million, operating profit of $98.5 million, and updated full-year 2026 guidance. The filing includes consolidated financial statements and detailed discussion of quarterly performance, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:53.412022+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-08-05"},{"id":24975,"accession_number":"0001171843-26-005223","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing BioCryst's second quarter 2026 financial results, including total net revenue of $218.3 million, operating profit of $98.5 million, and updated full-year 2026 guidance. The filing explicitly states \"BioCryst Reports Second Quarter 2026 Financial Results\" and provides detailed financial statements and business updates, which is the hallmark of an earnings release disclosure under Item 2.02 (though filed under Item 7.01 as Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:53.412022+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-08-05"}]}